Cargando…

What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study

This paper addresses the SARS-CoV-2 vaccination progress in Australia. Globally, Australia was initially praised for its national COVID-19 response, reflecting well with regard to case numbers and mortality rates. However, Australia’s progress with its vaccine rollout has come under scrutiny. When c...

Descripción completa

Detalles Bibliográficos
Autores principales: Choiseul, Juliette Caroline, Emmerson, Paris Jade, Eslanloo Pereira, Turan, Hosseinalipour, Seyed-Moeen, Hasselgård-Rowe, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620945/
https://www.ncbi.nlm.nih.gov/pubmed/36417218
http://dx.doi.org/10.3390/epidemiologia2040040
_version_ 1784821431103651840
author Choiseul, Juliette Caroline
Emmerson, Paris Jade
Eslanloo Pereira, Turan
Hosseinalipour, Seyed-Moeen
Hasselgård-Rowe, Jennifer
author_facet Choiseul, Juliette Caroline
Emmerson, Paris Jade
Eslanloo Pereira, Turan
Hosseinalipour, Seyed-Moeen
Hasselgård-Rowe, Jennifer
author_sort Choiseul, Juliette Caroline
collection PubMed
description This paper addresses the SARS-CoV-2 vaccination progress in Australia. Globally, Australia was initially praised for its national COVID-19 response, reflecting well with regard to case numbers and mortality rates. However, Australia’s progress with its vaccine rollout has come under scrutiny. When compared globally, it fares very low in terms of the number of vaccine doses administered. This paper discusses the first three months of the vaccination process, and the challenges Australia faced during that time. Through an extensive literature review, data was collected on relevant topics concerning all aspects of the Australian COVID-19 situation. The following key points are discussed: the specific COVID-19 organisation at the federal vs. the state government levels, the Australian economy, the vaccine supply strategy, and the vaccine priority roll out. In conclusion, we highlight the impact of Australia initially relying heavily on the AstraZeneca vaccine, which subsequently came under fire regarding safety issues likely linking the vaccine to thrombosis with thrombocytopenia syndrome (TTS).
format Online
Article
Text
id pubmed-9620945
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96209452022-11-18 What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study Choiseul, Juliette Caroline Emmerson, Paris Jade Eslanloo Pereira, Turan Hosseinalipour, Seyed-Moeen Hasselgård-Rowe, Jennifer Epidemiologia (Basel) Case Report This paper addresses the SARS-CoV-2 vaccination progress in Australia. Globally, Australia was initially praised for its national COVID-19 response, reflecting well with regard to case numbers and mortality rates. However, Australia’s progress with its vaccine rollout has come under scrutiny. When compared globally, it fares very low in terms of the number of vaccine doses administered. This paper discusses the first three months of the vaccination process, and the challenges Australia faced during that time. Through an extensive literature review, data was collected on relevant topics concerning all aspects of the Australian COVID-19 situation. The following key points are discussed: the specific COVID-19 organisation at the federal vs. the state government levels, the Australian economy, the vaccine supply strategy, and the vaccine priority roll out. In conclusion, we highlight the impact of Australia initially relying heavily on the AstraZeneca vaccine, which subsequently came under fire regarding safety issues likely linking the vaccine to thrombosis with thrombocytopenia syndrome (TTS). MDPI 2021-12-03 /pmc/articles/PMC9620945/ /pubmed/36417218 http://dx.doi.org/10.3390/epidemiologia2040040 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Choiseul, Juliette Caroline
Emmerson, Paris Jade
Eslanloo Pereira, Turan
Hosseinalipour, Seyed-Moeen
Hasselgård-Rowe, Jennifer
What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study
title What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study
title_full What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study
title_fullStr What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study
title_full_unstemmed What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study
title_short What Can Be Learned from the Early Stages of the COVID-19 Vaccination Rollout in Australia: A Case Study
title_sort what can be learned from the early stages of the covid-19 vaccination rollout in australia: a case study
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620945/
https://www.ncbi.nlm.nih.gov/pubmed/36417218
http://dx.doi.org/10.3390/epidemiologia2040040
work_keys_str_mv AT choiseuljuliettecaroline whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy
AT emmersonparisjade whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy
AT eslanloopereiraturan whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy
AT hosseinalipourseyedmoeen whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy
AT hasselgardrowejennifer whatcanbelearnedfromtheearlystagesofthecovid19vaccinationrolloutinaustraliaacasestudy